Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage biopharmaceutical company focused on engineered stem cell-based delivery platforms for oncolytic virus cancer therapies, targeting indications including glioblastoma and other solid tumors. The company became publicly traded in September 2023 through a business combination with First Light Acquisition Group, a SPAC sponsored by First Light Capital Group. Operating in the oncology and cell-and-gene-therapy sector, Calidi has advanced its NeuroNova and SuperNova platforms through early-phase clinical trials. The company filed an 8-K with the SEC on August 13, 2026, disclosing a material corporate event. For complete filing history, pipeline data, and SPAC transaction details on Calidi Biotherapeutics and hundreds of other deals, create a free account at SpacDesk.